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Abstract
To appraise published studies on the use of supplemental oxygen in chronic heart failure. Chronic breathlessness is a
characterizing symptom of symptomatic heart failure resulting in substantial disability and healthcare utilization and is
the primary reason for emergency room visits and hospitalizations. In spite of the variable evidence, oxygen therapy is
commonly administered both acutely and chronically. Moreover, the role of oxygen therapy to relieve chronic breath-
lessness in heart failure is not well described, particularly in normoxemic or mild or intermittent hypoxemic states. In
fact, several studies have shown the detrimental effects of oxygen therapy with normal oxygen saturation levels. A
systematic review using PRISMA guidelines. Four databases PubMed, Embase, CINAHL, and Web of Science were
systematically searched from January 2001 to January 2019 investigating the use of oxygen in heart failure. Duplicate
articles were removed from the review. Titles and abstracts were screened for inclusion and exclusion criteria. The
remaining full-text articles were reviewed and hand-searched for additional references. The quality of the full-text
articles was assessed using standardized critical appraisal instruments by the Joanna Briggs Institute. A total of 11
studies, including three intervention and eight non-interventions studies, were included in this review from 1072 non-
duplicated records retrieved. Sample size ranged from 4 to 5862. In spite of common usage, this review suggests that
there are scant data available to justify the use of oxygen in individuals with non-hypoxemic chronic heart failure and
chronic breathlessness.
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Introduction
Heart failure is a condition where the heart is unable to fill or
pump adequate blood to supply body’s demand and is a life-
threatening chronic illness and the final pathway of many car-
diovascular conditions [1]. Heart failure affects over 26 million
people globally and the prevalence of heart failure is growing
rapidly in both developed and developing countries worldwide
[2]. It is a global health problem and the leading cause of death.
In the USA, nearly 5.7million adults are livingwith heart failure
and nearly half of those die within 5 years of diagnosis [3].
Chronic breathlessness is a sentinel symptom of chronic
heart failure affecting 50–70% of individuals and known to
increase in intensity as disease progresses and particularly
towards the end of life [4]. High symptom burden, disability,
and reduced quality of life are common in both acute and
chronic heart failure [4]. Chronic breathlessness is the sensa-
tion or perception of shortness of breath and a leading cause of
emergency room visits and hospitalization in heart failure [5].
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It is also both the experienced sensation as well as the reaction
to adverse stimuli [6] and has been defined as Ba chronic
syndrome that persists despite optimal treatment of the under-
lying pathophysiology and that results in disability^ [7].
Treatment approaches for chronic breathlessness vary with
sparse evidence to inform treatment [8]. In many conditions,
patients’ prognosis may be better predicted by severity of
breathlessness rather than physiological measures [6].
Oxygen therapy has been commonly prescribed to manage
breathlessness in heart failure acutely and chronically in spite
of poorly defined efficacy [5]. Although some oxygen-use
studies have shown reductions in the intensity of breathless-
ness in patients with acute heart failure [9], currently there are
no studies demonstrating the effectiveness and efficacy of
long-term oxygen therapy in chronic heart failure for the
symptomatic reduction of chronic breathlessness [5].
Moreover, there is a lack of research defining whether having
an access to oxygen as needed (PRN) at home would reduce
the need for hospital admissions for people with chronic
breathlessness [5]. While oxygen therapy is commonly used
to alleviate suffering from hypoxia with breathlessness in
chronic heart failure, there is no evidence to inform the use
of oxygen in chronic heart failure patients with chronic breath-
lessness alone [5]. Additionally, several studies have shown
that hyperoxia can cause vasoconstriction in the cerebral, cor-
onary, and systemic vasculature [10], and there are similar
controversies regarding the use of oxygen in acute heart fail-
ure (AHF) [9]. Previous studies have concluded that excessive
oxygen use could be detrimental to cardiac function with re-
duced stroke volume and cardiac output [9]. Understanding
the role of oxygen to relieve breathlessness is predicated on an
understanding of the pathophysiology and management of
acute and chronic breathlessness. As heart failure manage-
ment moves from the hospital to the community and hospital
avoidance is a high priority, this is of increasing importance.
Pathophysiology of chronic breathlessness
Chronic breathlessness is caused by multiple factors and
symptoms vary by intensity, unpleasantness, and a person’s
functional and emotional response [11]. This subjective symp-
tom of shortness of breath often experienced by patients ac-
counts for approximately half of tertiary hospital admissions
for all patients [12]. The aetiology of breathlessness can be a
mix of physiological, pathological, psychological, social, and
environmental factors [13]. Breathlessness occurs most com-
monly due to compromised respiratory or cardiovascular sys-
tems, along with metabolic disorders, psychosocial condi-
tions, and neuromuscular disorders [12]. More importantly,
90% of breathlessness is caused by heart failure, myocardial
ischemia, chronic obstructive pulmonary disease (COPD),
pneumonia, asthma, and psychological disorders [12].
Biopsychosocial causes of breathlessness include pain,
distress, psychosocial problems, anger, panic attacks, and anx-
iety [13]. These conditions are known to increase respiratory
work, air hunger, urge/need to breathe, or tightness caused by
mismatch of pulmonary ventilation and the respiratory drive
to breathe increases [13]. When breathlessness occurs, affer-
ent receptors in the airways, chest and lung wall structures,
and central respiratory motor activity are not matching [12].
Afferent and efferent receptors and central nervous system
structures are involved in the development of breathlessness
[13]. Afferent receptors are found in the airways, chest, and
lung wall structures and are chemoreceptors that sense chang-
es in the arterial blood pH, carbon dioxide, and oxygen satu-
ration [13]. The central chemoreceptors sense the changes in
arterial blood pH and CO2 [13]. Chemoreceptors in the carotid
bodies receive information from medulla about the blood gas
levels of oxygen (O2), carbon dioxide (CO2), and hydrogen
(H+) [12]. When CO2 increases, chemoreceptors are stimulat-
ed to increase the respiratory motor activity [13]. The build-up
of H+ lowers the pH level in body, known as respiratory aci-
dosis. Efferent signals descend to the diaphragm and when the
central processing in the brain senses a mismatch between the
afferent and efferent signals, it results in breathlessness [12].
In other words, breathlessness occurs when the need for ven-
tilation (afferent signals) and physical breathing (efferent sig-
nals) is not matched [12]. The job of afferent receptors is to
assess if the efferent is signalling to the ventilatory muscle
effectively and the required demands such as air pressure, air
flow, and lung movement are being met [12]. When they are
not responding to each other appropriately, the intensity of the
breathlessness increases [12]. The breathlessness and con-
scious sensation of muscular effort are the result of motor
signals being sent to the chest wall while the sensory cortex
is activated [13].
Breathlessness and anxiety cycle
Understanding the relationship between anxiety and acute
breathlessness is important in considering the use of oxygen
therapy, particularly in the context of socialized response [14].
Likely in many healthcare encounters when an exacerbation
of chronic breathlessness acutely worsens, oxygen is admin-
istered. The respiratory sensations are influenced by neural
processing, occurring in the insular cortex, anterior cingulate
cortex, and amygdala of the brain [15, 16]. While this exact
same area of the brain controls pain, anxiety, anticipation of
breathlessness, fear of breathlessness, and sense of inability to
control the breathlessness, it is also correlated with increased
brain activations of anticipation and perception of induced
breathlessness [16]. Several previous studies on breathless-
ness and neuroimaging have shown the relationship between
perception of breathlessness and emotional processing [15].
The perception of breathlessness is caused by two primary
components: the sensory (intensity) and affective
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(unpleasantness) components [17]. Then, it is followed by
secondary component: cognitive affective, such as emotional
responses (suffering), which affects breathlessness related be-
havior in the future [17]. Moreover, the perception of breath-
lessness is influenced by physiology, pathophysiology, and a
complex interplay of mood, anxiety, emotional disposition,
and anticipation resulting in a cycle of breathlessness and
anxiety experiences [17]. It is also not unrealistic to suggest
that individuals with heart failure who have had multiple in-
teractions with the health system anticipate oxygen therapy in
breathlessness. In fact, Sepehrvand and colleague comment
that Boxygen therapy remains a cornerstone of acute heart
failure treatment in practice, but guidelines provide variable
recommendations on its appropriate use.^ This underscores
the expectations of patients when breathless [9].
In a more recent study, Booth et al. emphasize the impor-
tance of understanding the clinical breathlessness model con-
sists of breathing, thinking, and functioning [6]. While a pa-
tient is experiencing breathlessness, there are three factors
driving the vicious cycle of breathlessness. When a patient is
experiencing breathlessness, it is compensated by the use of
accessory muscles as along with increased respiratory rate,
which leads to thoughts and fear of dying along with sense
of panic and increased anxiety level, which then lead to de-
creased physical activities as a natural response to reserving
more energy [6].
Current management strategies for chronic
breathlessness
There are three main breathlessness management strategies that
are used in clinical practice, particularly in chronic states: non-
pharmacological approaches including pulmonary rehabilitation,
supplemental oxygen, and pharmacological therapies.
Combining pharmacological and non-pharmacological interven-
tions, such as regular oral low-dose extended release morphine
and pulmonary rehabilitation, has been shown to be effective in
managing chronic breathlessness among advanced chronic ob-
structive pulmonary disease patients [11]. There is also an in-
creasing number of breathlessness clinics that recognize the
complex and multifaceted nature of this symptom. The majority
of advanced heart failure management occurs at home and com-
munity settings, which involves patients and their carers. It is
essential to integrate self-care plan, knowledge, and strategies
in individual’s daily chronic heart failure care [18].
Supplemental oxygen is often used for chronically hypox-
emic patients. Supplemental oxygen works by changing che-
moreceptor stimulation and breathing pattern; however, the
effectiveness of relieving breathlessness varies [12]. A previ-
ous meta-analysis demonstrated that long-term oxygen thera-
py may improve survival in patients with severe hypoxemia
[19]. However, when used with patients mild to moderate
hypoxemia, it did not improve survival [19]. Moreover, the
use of long-term supplemental oxygen of at least 15 h a day,
including overnight for individuals with COPD with hypoxia
at rest, has shown reduction in mortality after over 1 year of
therapy [19]. Furthermore, ambulatory oxygen therapy (the
use of oxygen during exercise and activities of daily living)
has been used among patients with COPD with or without
resting hypoxemia and has demonstrated improvement in ex-
ercise capacity and quality of life in fatigue domain [20]. Yet
in heart failure, data is scarce.
Pharmacological therapy often entails using opioids.
Short-term use of opioids reduces breathlessness, especially
in advanced COPD, other lung disease, and cancer patients
[12]. While opioids have been commonly prescribed to treat
COPD patients with chronic musculoskeletal pain and uncon-
trollable breathlessness, opioids can be harmful by causing
hypoventilation and cough suppression which leads to re-
duced mucous clearance [21]. A previous study highlighted
the increased risk of respiratory-related mortality and all-cause
mortality when opioid is used among older adults with COPD
[21]. L-menthol has been used in some clinical settings and
has been shown to relieve exercise-induced dyspnea in
healthy subjects [22]. Although the effect of the L-menthol-
derived cooling sensation has not been fully understood, it
may be used to relieve breathlessness by stimulating olfactory
temperature-sensitive sensory neurons [22]. Despite benzodi-
azepines being widely used to relieve breathlessness in ad-
vanced diseases, their propensity to cause drowsiness and rap-
id tolerance limits them to second- or third-line treatment,
when other options have failed [23].
Pulmonary rehabilitation is often used in the management
of chronic lung diseases [12]. Oftentimes, pulmonary rehabil-
itation programs include exercise, as well as education, dietary
advice, psychological support, and assessment in some cases
[24]. This reduces exertional breathlessness during exercise
and improves exercise tolerance and activity level [25].
Among patients with COPD patients, pulmonary rehabilita-
tion has demonstrated to relieve breathlessness and fatigue,
enhance the patient’s sense of control, and improve health-
related quality of life [24]. Heart failure-specific cardiac reha-
bilitation also improves cardiovascular function.
Other non-pharmacological approaches such as directing
cool/cold air on the face have shown to reduce breathlessness
in healthy individuals [12]. Some patients feel subjective relief
of breathlessness when sitting in front of a fan or an open
window [22]. A randomized control study found a handheld
fan blowing air to the face reduce intensity of breathlessness
among individuals with advanced disease [5, 6]. Yet, the
mechanism of the effect of air therapy is still unknown [22].
Use of oxygen therapy
Oxygen therapy is variably prescribed to manage breathless-
ness in heart failure, partly because patients with severe lung
Heart Fail Rev
disease who are hypoxemic at rest, with exertion, or during
sleep benefit from long-term oxygen therapy, in which oxygen
therapy can prolong survival [19]. The adherence rate of ox-
ygen therapy prescription is generally lower than the clinical
trials that inform the clinical practice due to its cumbersome
nature and requirement for delivery systems that are often
noisy and difficult to manage [5]. In addition, oxygen therapy
may cause irritation to the nose and presents a social stigma
for the patient [5]. For these reasons and others, oxygen ther-
apy can be burdensome for patients and their families [5].
Breathlessness in heart failure is caused by complex car-
diopulmonary interactions rather than cardiovascular factors
alone [26] and the burden of comorbidities should also be
underscored. Shortness of breath without objective signs of
pulmonary congestion is a common early symptom of heart
failure with preserved ejection fraction (HFpEF) and heart
failure with reduced ejection fraction (HFrEF) [27].
Although a few oxygen-use studies have reported improve-
ment in symptoms and intensity of breathlessness in patients
with acute heart failure and hypoxia, there are no studies that
support the safety and efficacy of long-term home oxygen
therapy administered to chronic heart failure patients without
hypoxia [5]. To date, there are a lack of data examining wheth-
er access to oxygen therapy at homewould reduce the need for
hospital admission [5]. Furthermore, a systematic review on
the use of oxygen therapy to relieve breathlessness in chronic
end-stage disease conducted by Cranston et al. underscored
the inability to draw conclusions due to the small numbers of
participants and limited numbers of research studies available
[19]. Current research suggests that long-term oxygen therapy
should not be used in patients with chronic heart failure due to
the lack of evidence supporting the benefit in relieving breath-
lessness and also the absence of harm [5]. Although a few
previous studies highlighted a positive relationship between
duration of oxygen and improved symptoms, the mechanism
of improved symptoms and the impact on prognosis remain
unclear [5]. Yet in spite of this, oxygen administration is com-
monly undertaken in inpatient, outpatient, and community
settings [5].
There are three main oxygen delivery systems that are used
in current clinical practice: conventional oxygen therapy,
high-flow nasal oxygen therapy, and non-invasive or invasive
ventilation. This review pertains to the use of oxygen in the
management of breathlessness in the absence of hypoxemia.
The aim of this review was to identify existing literature de-
scribing the use of oxygen to relieve breathlessness in HF.
Methods
This systematic review adheres to the PRISMA reporting
guidelines for systematic reviews to identify relevant peer-
reviewed published articles.
Search methods
The electronic databases PubMed, Embase, CINAHL, and
Web of Science were searched from January 2001 to
January 2019 under the supervision of a health librarian.
Search criteria were created using the medical subject head-
ings (MeSH) and non-MeSH search terms: Bheart failure,^
Bcardiac failure,^ Bheart decompensation,^ Bmyocardial
failure,^ Bcongestive heart failure,^ Boxygen inhalation
therapy,^ Boxygen therapy,^ Boxygen use,^ Badult,^ and
Badult patient,^ Bdyspnea,^ and Bbreathlessness.^ In addition,
a manual search of relevant literature and reference list was
performed to identify applicable studies to this review.
Inclusion and exclusion criteria
Published studies were included if the review (1) included
a heart failure population, (2) addressed the use of oxygen
in chronic heart failure, and (3) included other chronic
illnesses, if 25% of the included population had heart fail-
ure. Articles were excluded if the study focused on (1)
pediatric populations, (2) left ventricular assist device
(LVAD) or implantable cardiac defibrillator (ICD) popula-
tions, (3) sleep disordered and sleep apnea populations, (4)
non-English publications, and (5) reviews, editorials,
guidelines, or conference abstracts.
Search outcome
The search resulted in 1159 relevant citations and were
imported into a web-based systematic review software pro-
gram (Covidence®). Eighty-seven duplicates were removed,
resulting in 1072 articles. Titles and abstracts were reviewed
against inclusion and exclusion criteria, which resulted in the
exclusion of 935. The full text of the remaining 137 articles
were assessed and 7 were excluded as non-English publica-
tions and another 119 articles were excluded because they
either did not address heart failure population, focused on
pediatric population, or were reviews, systematic reviews, let-
ters to editor, guidelines, or conference abstract. A total of 11
articles were included in this review (Fig. 1).
Data abstraction
Data extraction from 11 articles were undertaken using a data
extraction form, summarizing study design, sample character-
istics, and summary of study findings (Table 1) [28]. Data
were categorized as intervention studies and non-
intervention studies, using the guidance on the conduct of




The majority (n = 8) of the 11 eligible studies were non-
intervention studies. Of the three intervention studies, there
were two randomized control trials (RCTs) [5] and one
experimental study [29]. Non-intervention studies included
three observational studies [30]–32], one cohort study [33],
two descriptive studies [34, 35], one case series [36], and
one retrospective observational study [37]. Synthesized in-
formation on research design, sample size, and character-
istics and findings is presented in Table 1. Studies were
conducted in the USA, UK, Australia, Japan, and Europe
(Turkey, Spain, France, and Netherlands). The majority of
participants were male in all three intervention studies as
majority of other heart failure study subjects are usually
male. Most of the studies were undertaken in hospitals,
several in outpatient centers, and a single study at home.
Participants included New York Heart Association
(NYHA) I−II [38], II−III [29, 35], III [36], and III−IV
[5]. Ages ranged between 56 and 97 years old with the
median age of 76.5.
Intervention study findings
Long-term oxygen therapy In the inadequately powered RCT
conducted in the UK, individuals with severe chronic heart
failure (NYHA Class III−IV), recruited from the hospital out-
patient clinics or the community (both urban and rural set-
tings), were randomized (n = 114) to receive either long-term
oxygen therapy prescribed for 15 h per day including over-
night at approximately 28% oxygen while the control group
(n = 51) received best medical therapy alone for 6 months [5].
This RCT showed no impact on quality of life measured by
Minnesota Living with Heart Failure Questionnaire score at
6 months [5]. The quality of life score was lower among the
long-term oxygen therapy group at 3 months [5].
Breathlessness scores improved in oxygen group at 3 months.
However, there was no effect on 6-min walk test distance, N-
terminal pro b-type natriuretic peptide (NTproBNP) level, and
left ventricular ejection fraction in the oxygen group [5].
Although the survival rate was slightly better in the oxygen
group, there was no statistically significant difference between
two groups [5]. This RCTwas significantly underpowered and
only 11% of the participants adhered to oxygen as prescribed
[5]. This RCT was stopped early by the funders due to poor
patient adherence to home oxygen [5].
In an open label experimental study, 10 patients with
NYHA classes II and III chronic heart failure received home
oxygen for a minimum of 8 h at night at a flow rate of 4 L/min
via nasal cannula for 4 weeks [29]. After a month of nocturnal
oxygen therapy, the functional status measured by the 6-min
walk test improved clinically significantly by 53 m (17.8%
increase) [29]. The quality of life measured by Minnesota
Living with Heart Failure (MLWHF) also improved by 7 units
(26.9% increase) [29]. Considering the minimally significant
clinical difference for MLWHF is 7.27 [39], the seven-unit
improvement is moderately significant. However, there was
no improvement in systolic and diastolic functionwith oxygen
therapy or change in the baseline ejection fraction, stroke vol-
ume, or NTproBNP level with the oxygen therapy [29]. The
authors concluded that although home oxygen therapy may be
useful in chronic heart failure population, further randomized
blinded studies are needed to confirm the findings and to
determine the effects of oxygen use at night on mortality and
re-hospitalization [29].
Effectiveness of acute oxygen/gas use In a phase III RCT
conducted in an acute care hospital setting, 13 men with
NYHA Class I−II heart failure and left ventricular systolic
dysfunction were administered medical air or 40% oxygen at
a flow rate of 10 L/min for 15 min, followed by high-
concentration oxygen at flow rate of 15 L/min via Hudson
non-breathing mask for another 15 min. The effects of oxygen
use were complex [38]. Specifically, the supplemental oxygen
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contrary to previous studies, oxygen did not change plasma
natriuretic peptide concentrations [38]. The authors of this
RCT concluded that the effect of oxygen may vary by the
severity of heart failure and that unnecessary oxygen treat-
ment (in the absence of hypoxemia) may be detrimental in
patients with decompensated heart failure [38].
Patient’s perception of oxygen use A qualitative sub-study of
a long-term home oxygen therapy RCT revealed that partici-
pants did not adhere to oxygen therapy as prescribed, because
they believed that oxygen use is for acute deterioration or for
end of life [5]. Moreover, misunderstanding of the indication
for oxygen use was making patients see long-term oxygen
therapy as a burden rather than a benefit [5]. Many patients
referred to oxygen therapy as an Baltruistic act and as a way of
accessing optimal clinical care^ [5].
Non-intervention study findings
Out of eight eligible non-intervention studies, five of them
specifically focused on heart failure (acute (n = 2) and chronic
(n = 3) heart failure and the population mix of the other two
studies included patients with heart failure and either lung
cancer or respiratory failure. Out of all the non-intervention
studies, two of them focused on patients at the end of life
specifically [30, 32].
Oxygen use in breathlessness In a descriptive study using a
nationwide French survey, DeFSSICA, out of 699 breathless-
ness patients with suspected AHF who were admitted to an
emergency department, 2/3 were administered furosemide and
oxygen for breathlessness [34]. In this study, majority of pa-
tients (77%) with suspected breathlessness had AHF and that
patients with AHF were older compared to non-AHF patients
and 40% of them had history of hospitalization for AHF in the
previous year [34]. In a cohort study conducted in Australia,
21% of the palliative care patients with chronic breathlessness
were prescribed home oxygen and one-third of them had sig-
nificant improvement in breathlessness; however, overall re-
sults showed no clinically significant improvement in breath-
lessness despite the oxygen administration [33]. The authors
of this study highlighted that the role of oxygen remains un-
clear and there is a lack of studies to measure the impact of
oxygen on quality of life and breathlessness in the heart failure
population [33].
High-flow therapy A retrospective review of electronic medi-
cal record files reported an increase in the use of high-flow
nasal cannula oxygen therapy with better survival among
heart failure patients hospitalized with pneumonia [40]. The
most common uses of high-flow nasal cannula were for pneu-
monia and chronic heart failure patients due to hypoxic respi-




































































































































































































































































































































































































































































































Japan, four acute heart failure patients with refractory hypoxia
were treated with high-flow nasal oxygen therapy after failing
conventional oxygen therapy [33]. Mean duration of this ther-
apy was 6.0 ± 3.7 days without respiratory distress relapse for
all four patients [33]. Although this study did not report the
oxygen use during the course of 24 h, the authors highlighted
the benefit of high-flow therapy among acute heart failure
patients with hypoxia who failed conventional oxygen therapy
first [31].Although previous studies have found improvement
in oxygenation using high-flow oxygen [31, 40], most hospi-
tals use high-flow nasal cannula therapy without policy [40].
In a study conducted in Spain, 10 patients with NYHA class
III heart failure were administered humidified high-flow gas
via nasal cannula, delivered in two consecutive 30-min pe-
riods at a flow rate of 20 L/min, then increased to 40 L/min
[36]. A significant decrease in respiratory rate was observed in
the participants suggesting that high-flow nasal cannula treat-
ment may be beneficial in this population [36].
Gender preferenceWhile breathlessness was reported by 61%
of the participants with NYHA class II and III chronic heart
failure in a descriptive study conducted in Turkey, there were
gender differences in terms of preferred breathlessness man-
agement [35]. While 65% of men preferred resting as breath-
lessness management, 81% of women preferred oxygen ther-
apy and diuretics (p = 0.004) [35].
Oxygen use at end of life care Long-term oxygen therapy can
be burdensome to both patients and caregivers as evidenced
by adverse nasal effects, limited mobility, noisy compressors,
cost, invaded space, and increased fire hazard [30]. While
oxygen therapy can be useful with distressed or hypoxemic
patients at the end of life, there is a lack of evidence to support
the initiation or continuation of oxygen therapy among end of
life heart failure patients who are not distressed or hypoxemic
[30]. In a prospective nationwide survey in France, it was
found that while all heart failure patients received opioid, only
7% of them received oxygen therapy [34].
Discussion
This systematic review highlights the lack of evidence for the
use of oxygen in the HF population living with chronic breath-
lessness and some warnings about the potential dangers of
using long-term oxygen therapy in this population. While
RCTs included in this systematic review were both inade-
quately powered, RCTs generate the highest level of evidence.
In both RCTs, the result of oxygen use was conflicting in
terms of quality of life and relieving breathlessness. It was
underscored that oxygen use may be detrimental when used
in non-hypoxemic patients. The diversity and heterogeneity of
study populations and outcome measures precluded meta-
analysis. Moreover, only one study was undertaken among
NYHA Class III and IV heart failure population on oxygen
use. We also know that heart failure is a syndrome commonly
associatedwith comorbidity and frailty and that breathlessness
can be caused by deconditioning and other factors. Although
the administration of oxygen therapy to relieve breathlessness
in patients with heart failure is widely practiced, there is a lack
of evidence to inform the use of oxygen in chronic heart fail-
ure. While a few oxygen-use studies have shown improve-
ment in symptoms and intensity of breathlessness in acute
heart failure, its safety and efficacy for chronic heart failure
patients are understudied. Moreover, perception of breathless-
ness is heavily influenced by psychological and behavioral
factors, such as anxiety, which is known to worsen future
breathlessness. In order to provide optimal care that improves
symptom management, quality of life, and prevents needless
hospitalizations, better understanding of breathlessness man-
agement is needed. This will likely involve a more compre-
hensive understanding of not only the pathophysiology but the
experience of breathlessness.
Implications for future research
This review has highlighted the importance of understanding
the complexity of oxygen use from pathophysiology to psy-
chosocial factors that may contribute to breathlessness symp-
toms. A recent systematic review in interstitial lung disease
showed no effects of oxygen therapy on breathlessness during
exercise, although exercise capacity was increased,
underscoring the complexity of understanding mechanisms.
Despite the common use of oxygen, future research is needed
to investigate whether oxygen use in advanced heart failure
population (NYHA III−IV) is useful or harmful and whether
this therapeutic approach should be integrated with a compre-
hensive breathlessness management program to decrease
symptom burden and improve quality of life.
Implications for clinical practice
This review underscores the conflicting results of oxygen use
in heart failure population and the lack of evidence to inform
guidelines in identifying the potential candidates that may
benefit from oxygen administration, particularly in the pallia-
tive care setting.
Limitations
While we used a rigorous approach in systematically
reviewing the existing literature, there may be a possibility
we did not capture all relevant studies. Some studies did not
have heart failure as their primary focus and detailed informa-
tion may have been left out from their findings that may be
relative to oxygen use in heart failure. This is particularly
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important in the context of multimorbidity and heart failure
which is often a cardiogeriatric syndrome. There is also a lack
of diversity as majority of participants were male.
Furthermore, majority of the studies used convenient samples.
These may limit the generalizability of the findings. In spite of
these limitations, this systematic review highlights the current
lack of evidence for oxygen use in heart failure population.
Conclusion
This review underscores the complexity of oxygen use in chron-
ic heart failure populations. There are conflicting findings that
oxygen use in heart failure may not be associated with improv-
ing quality of life or relieving breathlessness. In some cases,
administration of oxygen may be harmful for this population.
In spite of the common use of oxygen in chronic heart failure, a
clear finding from this review is that there are scant data avail-
able and a lack of randomized clinical trials of oxygen use in
heart failure populations. The fact is that only two studies were
RCTs of varying quality and only one study was undertaken
among NYHA Class III and IV heart failure populations on
oxygen use which highlights a fertile ground for examining
oxygen use in advanced heart failure populations.
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Appendix
( BOx y g e n u s e ^ OR Bo x y g e n t h e r a p y ^) AND
(Bbrea th lessness^ OR Bdyspnea^) AND ((BHear t
Fa i lure^[Mesh] OR Bcard iac fa i lure^ OR Bhear t
decompensation^OR Bheart failure^OR Bmyocardial failure^
OR Bchf^ [tiab]))
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